Retatrutide — Education Page Only (Triple-Agonist)

⚠️ Regulatory Notice

Retatrutide (LY3437943) is an investigational research compound Eli Lilly and Company that is
not approved as a medicinal product in the UK. In line with MHRA guidance on unlicensed medicines and our internal compliance policy, this compound is not available for purchase or distribution through Adonis Elite Peptides.

This page is maintained for educational and scientific reference purposes only, reflecting publicly available literature on
incretin-based receptor pharmacology and related signalling studies. No supply, sale, dosing guidance, or promotional claims are offered or implied.

All information is intended strictly for research education and scientific context. Not for human or veterinary use.

Not for human or veterinary use. No medical or therapeutic claims.

Retatrutide (Triple Agonist Peptide)

Retatrutide is a novel triple agonist peptide that targets the GLP-1, GIP, and glucagon receptors, making it one of the most advanced compounds in current metabolic regulation and weight management research. By activating these three key metabolic pathways, Retatrutide may offer insights into how the body regulates glucose, lipids, and energy balance.

For detailed analysis and supporting studies, visit our Retatrutide Research Blog.

Peptide Information

Name:	Retatrutide (LY3437943)
Synonyms:	LY3437943, GLP-1/GIP/Glucagon Receptor Agonist
CAS Number:	N/A
Molecular Formula:	C₂₀₃H₃₁₇N₅₅O₆₆
Molecular Weight:	≈ 4500 g/mol
Sequence:	Proprietary peptide sequence (GLP-1/GIP/Glucagon receptor agonist)
Form:	N/A
Purity:	N/A
Storage:	N/A

Overview

Retatrutide peptide represents a new frontier in incretin-based peptide research. It acts on three metabolic receptors — GLP-1, GIP, and glucagon — providing a multifaceted approach to studying metabolic balance, glucose control, and lipid oxidation. Clinical trials are exploring Retatrutide for its potential to improve insulin sensitivity, enhance energy expenditure, and modulate appetite-regulating mechanisms in preclinical models.

Potential Clinical Applications

Triple agonist metabolic pathway
Glucose regulation and insulin sensitivity
Obesity and weight management mechanisms
Energy expenditure and lipid oxidation models
Endocrine and mitochondrial signalling

Scientific Background

Retatrutide is part of a new class of incretin-mimetic peptides that stimulate multiple metabolic receptors. By activating GLP-1 and GIP receptors, Retatrutide enhances insulin secretion and glucose control, while the glucagon receptor activation increases energy output and fat metabolism. Early trials indicates synergistic effects greater than dual agonists like tirzepatide, suggesting Retatrutide may advance understanding of metabolic homeostasis in laboratory settings.

Got Questions or want to stay Informed on Current Research?

Retatrutide is currently being studied in various clinical and laboratory settings worldwide. As new data becomes available, many in the research community are keen to stay informed.

If you’d like updates on published studies, trial progress, and scientific insights:

???? Join our research updates list here:

Or speak with our research support team:

Email: [email protected]

*All discussions are strictly educational research in nature.*

Disclaimer

Retatrutide is currently in clinical trials and cannot be legally sold or distributed outside of legal regulatory frameworks.

All information is intended strictly for research education and scientific context. Not for human or veterinary use.

Retatrutide — Education Page Only (Triple-Agonist)

⚠️ Regulatory Notice

Not for human or veterinary use. No medical or therapeutic claims.